SB202190 (FHPI)

Catalog No.S1077

SB202190 (FHPI) Chemical Structure

Molecular Weight(MW): 331.34

SB202190 (FHPI) is a potent p38 MAPK inhibitor targeting p38α/β with IC50 of 50 nM/100 nM in cell-free assays, sometimes used instead of SB 203580 to investigate potential roles for SAPK2a/p38 in vivo.

Size Price Stock Quantity  
In DMSO USD 134 In stock
USD 147 In stock
USD 370 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

3 Customer Reviews

  • C, Jurkat cells with SB202190 at 1, 5, and 10 μM were tested, and a decreased SRP72 expression was found when using at 10 μM (lanes 8 and 9). D, results were analyzed and RUA illustrated, finding significant results at 10 μM at 240 versus 0 and 120 versus 0 min (p<0.05).

     

     

    J Biol Chem 2010 285, 32824–32833. SB202190 (FHPI) purchased from Selleck.

    C, effect of SB202190 (1, 5, and 10 μM) on SRP72 phosphorylation was tested. A decreased intensity of SRP72 expression when used at 1 μM (240 min) and 5 and 10 μM (120 and 240 min) was found. D, RUA illustrated obtaining significant results at concentration 5 and 10 μM at 120 versus 0 and 240 versus 0 min. * indicates p<0.05.

     

     

    J Biol Chem 2010 285, 32824–32833. SB202190 (FHPI) purchased from Selleck.

  • We used real time RT-PCR to investigate the effects of SB202190 on SRP72 mRNA expression. All the samples were treated under the same experimental conditions used in protein tests done by WB, and phosphorylation was measured indirectly by IP-WB. The results did not show significant changes on the mRNA expression of SRP72 after the treatment with these inhibitors.

     

     

    J Biol Chem 2010 285, 32824–32833. SB202190 (FHPI) purchased from Selleck.

Purity & Quality Control

Choose Selective p38 MAPK Inhibitors

Biological Activity

Description SB202190 (FHPI) is a potent p38 MAPK inhibitor targeting p38α/β with IC50 of 50 nM/100 nM in cell-free assays, sometimes used instead of SB 203580 to investigate potential roles for SAPK2a/p38 in vivo.
Targets
p38α [1]
(Cell-free assay)
p38β [1]
(Cell-free assay)
50 nM 100 nM
In vitro

SB 202190 significantly inhibits both basal and anti-Fas antibody-induced MAPKAPK 2 activity in a dose-dependent manner. SB202190 by itself is sufficient to induce cell death in Jurkat and HeLa cells through activation of CPP32-like caspases, which can be blocked by expression of bcl-2. SB202190-induced apoptosis is attenuated by p38β but augmented by p38α. [2] SB 202190 strongly inhibits UVB induced COX-2 protein expression in HaCaT cells, and markedly inhibits UVB induced cox-2 mRNA. [3] SB 202190 treatment inhibits the expression of albumin-induced proinflammatory (monocyte chemoattractant protein-1) and transforming growth factor (TGF)-beta1-induced profibrotic (procollagen-Ialpha1) genes over 50% in renal tubular cells (normal rat kidney-52E). [4] SB 202190 treatment induces phosphorylation of JNK in a dose- and time- dependent manner in A549 cells, induces phosphorylation of ATF-2 transcription factor, and increases AP-1 DNA binding. [6] SB 202190 treatment enhances the growth of THP-1 and MV4-11 cells. SB 202190 increases the phosphorylation of c-Raf and ERK, suggesting that Ras-Raf-MEK-mitogen-activated protein kinase (MAPK) pathway activation is involved in the leukemia cell growth induced by SB 202190. [7]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
HCT-116 NXPSUVNkTnWwY4Tpc44hSXO|YYm= MnjLNlUh|ryP MoH3N|AhdWmw M4XhV2ROW00EoB?= Mk\YZZR1\W63YYTld{B1cGVibWLORUBidmRicILveIVqdiCneIDy[ZN{cW:wIH;mJIhDTC1{IHnuJJJme3CxboPpeoUhfG9iRFG= MYeyOlIzOzJ3MR?=
MDA-MB-231 NH7OVWdHfW6ldHnvckBCe3OjeR?= M3m4elIh|ryP M2K3dVI1KGh? NWHqNXRGdGW|c3Xu[ZMhS0OOMjDpcoR2[3Srb36gZpkhXE6IzsG= MnzXNlYyODB6NEi=
rBMSCs M4HXZ2Z2dmO2aX;uJGF{e2G7 M{fEbVExKM7:TR?= Mo\xNk42KGh? MX7k[ZBz\XO|ZYOgeIhmKHCqb4PwbI9zgWyjdHnvckBw\iCHUlugZY5lKHB|OB?= NYjqNZJ3OjZyNUOyOlY>
MG63 M1PPfGZ2dmO2aX;uJGF{e2G7 MVyxNE8zOC9|MDFOwG0> Mk\oNlQhcA>? M{XLZZNq\26rZnnjZY51dHliZHXjdoVie2W|IITo[UBt\X[nbDDv[kBxcG:|cHjvdplt[XSnZDDwN|ghcW6mdXPl[EBjgSCFZFPsNkBqdiCjIHPvcoNmdnS{YYTpc44hNWSncHXu[IVvfCCvYX7u[ZI> NIXKU5ozPTl7OEOxNi=>
MG63 MnzXRZBweHSxc3nzJGF{e2G7 NX;YXFUzOTBxMkCvN|Ah|ryP NI\PWZIzPCCq MnLrd4lodmmoaXPhcpRtgSCmZXPy[YF{\WRidHjlJIFxd3C2b4Ppd{Bz[XSnIH;mJG1IPjNiaX7keYNm\CCkeTDD[GNtOg>? Mlz5NlU6QTh|MUK=
HTSMCs NVfCXoxGTnWwY4Tpc44hSXO|YYm= NGjDSmMxNjFxMT:xNEDPxE1? NFnWW3QyKGh? MWTpcohq[mm2ZXSgR29TVS1{LXnu[JVk\WRiSF:tNUBxem:2ZXnuJIxmfmWuczDhcoQhdVKQQTDlfJBz\XO|aX;u M17HRlI2QTJzNE[0
MIA PaCa-2 MmjxSpVv[3Srb36gRZN{[Xl? M4m1bVIxyqEQvF2= MXOyOEBp M3ToTJJm\HWlZXSgcIFkfGG2ZTDhZ4N2dXWuYYTpc44hcW5iY3;tZolv[XSrb36ge4l1cCCkb4ToJFIuTEdiYX7kJGQu[Wyub4PlxsA> MmPxNlU5QDh2OEm=
MIA PaCa-2 M2jseWZ2dmO2aX;uJGF{e2G7 NFrYO4czOMLizszN M2X5OVI1KGh? NXf0UnpxemW|dXz0d{BqdiCjIH3v[IV{fCCrbnjpZol1cW:wIH;mJGhKTi1zzsGgdJJwfGWrbjDhZ4N2dXWuYYTpc44> MofONlU5QDh2OEm=
BxPC-3 NYrmb3JNTnWwY4Tpc44hSXO|YYm= NIrz[HgzOMLizszN M1u4dFI1KGh? M2jXUZJme3WudIOgbY4h[SCvb3Tld5QhcW6qaXLpeIlwdiCxZjDITWYuOc7zIIDyc5RmcW5iYXPjeY12dGG2aX;u MnjrNlU5QDh2OEm=
AsPC-1 MWHGeY5kfGmxbjDBd5NigQ>? M3HIVlIxyqEQvF2= NInJbWozPCCq MXzy[ZN2dHS|IHnuJIEhdW:mZYP0JIlvcGmkaYTpc44hd2ZiSFnGMVHPuSCycn;0[YlvKGGlY4XteYxifGmxbh?= NITlPFAzPTh6OES4PS=>
MIA PaCa-2 M2ew[GZ2dmO2aX;uJGF{e2G7 NYLo[W9EOjEEoN88US=> MV6yOEBp NHTs[YRmdmijbnPld{BkdGWjdnHn[UBw\iCSQWLQJJdp\W5iY3;tZolv\WRid3n0bEBodHWlb4PlJIFv[WyxZ4O= NGS5bXozPTh6OES4PS=>
MIA PaCa-2 NV64TWZtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUmyNOKh|ryP NEjPPIIzKGh? NWHDOnJLe2Wwc3n0bZpmeyClZXzsJIxqdmW|IITvJJRz\WG2bXXueEB4cXSqIEKtSGch[W6mIFStZYxtd3On MX[yOVg5QDR6OR?=
BxPC-3 NXX4PXFUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkHnNlDDqM7:TR?= M33YWVIhcA>? MYrz[Y5{cXSrenXzJINmdGxibHnu[ZMhfG9idILlZZRu\W62IIfpeIghOi2GRzDhcoQhTC2jbHzvd4U> M{Lm[|I2QDh6NEi5
AsPC-1 M3rDcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MljONlDDqM7:TR?= MmnaNkBp MXrz[Y5{cXSrenXzJINmdGxibHnu[ZMhfG9idILlZZRu\W62IIfpeIghOi2GRzDhcoQhTC2jbHzvd4U> MVmyOVg5QDR6OR?=
HEY Mn3MS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYrEb5NZOjEEoN88US=> MW[yJIg> MX3z[Y5{cXSrenXzJINmdGxibHnu[ZMhfG9idILlZZRu\W62IIfpeIghOi2GRzDhcoQhTC2jbHzvd4U> MVqyOVg5QDR6OR?=
OVCAR-3 M3:2Smdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH7JeoIzOMLizszN M4W2WFIhcA>? M1fQT5NmdnOrdHn6[ZMh[2WubDDsbY5meyC2bzD0doVifG2nboSge4l1cCB{LVTHJIFv\CCGLXHscI9{\Q>? M2HMR|I2QDh6NEi5
SK-OV-3 NGPwUG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYj3eWdLOjEEoN88US=> NWXlVlYxOiCq MlXzd4Vve2m2aYrld{Bk\WyuIHzpcoV{KHSxIITy[YF1dWWwdDD3bZRpKDJvRFegZY5lKERvYXzsc5Nm MkD0NlU5QDh2OEm=
MH7A  Mm[4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWW3SmJFOjRiaB?= NFHleGpz\WmwZn;yZ4V{KHSqZTDpcohq[mm2b4L5JIVn\mWldIOgc4YhYEGQ MmjtNlU5PjJ7Nk[=
MH7A  M2raXGFxd3C2b4Ppd{BCe3OjeR?= M4i0[FI2KM7:TR?= NHryNpczPCCq NUfUdZd{emW4ZYLz[ZMh[2WubDDjfYNt\SCjcoLld5QhcW6mdXPl[EBjgSC[QV6gZY5lKGOjdYPl[EBieG:ydH;zbZMhd2ZiY3XscJMhfmmjIHHjeIl3[XSrb36gc4YhUk6N MYCyOVg3Ojl4Nh?=
SCC25 NV3aO3d4TnWwY4Tpc44hSXO|YYm= NX\k[pRtOjBizszN MmrXNlQhcA>? MkG2bY5kemWjc3XzJIF2fG:yaHHnfUBt\X[nbB?= M4e3OFI2QDN2NECw
HaCaT  MYjGeY5kfGmxbjDBd5NigQ>? MkfwOUDDvU1? M4LmTVI1KGh? NEPhO4VqdmirYnn0d{BKTk5vzsOtbY5lfWOnZDDDR2wzOiCycn;keYN1cW:wIHzleoVtew>? MYWyOVg{PDN3Mx?=
HaCaT  MoX5SpVv[3Srb36gRZN{[Xl? M3zofVUhyrWP NWfDXJFiOjRiaB?= NHLBS3NqdmirYnn0d{BKTk5vzsGtbY5lfWOnZDDDR2wzOiCycn;keYN1cW:wIHzleoVtew>? NIDH[IMzPTh|NEO1Ny=>
HPAEpiCs  NFjOfFBHfW6ldHnvckBCe3OjeR?= M{j3bFEwOy9zMDFOwG0> MVqxJIg> NFvDcYVz\WS3Y3XzJHMyWC2rbnT1Z4VlKEmFQV2tNUBxem:2ZXnuJIFv\CCvUl7BJIV5eHKnc4Ppc44h[W6mIIDyc41wfGW{IHHjeIl3cXS7 MmXlNlU4OzR7MEC=
HPAEpiCs NW\jOJpsTnWwY4Tpc44hSXO|YYm= M2jwOlEwOy9zMDFOwG0> NH7aR3kyKGh? MmHibY5pcWKrdIOgV|FRNXO2aX31cIF1\WRiQXv0JJBpd3OyaH;yfYxifGmxbjCgxsA> M4D6SVI2PzN2OUCw
HPAEpiCs NXThS|R3TnWwY4Tpc44hSXO|YYm= MkPXNU8{NzFyIN88US=> MVOxJIg> M1jk[olvcGmkaYTzJHMyWCC2aX3lMYRmeGWwZHXueIx6KHO2aX31cIF1\WRiYz3KeY4heGixc4Doc5J6dGG2aX;u M37CeVI2PzN2OUCw
K562 NVf5SGpQTnWwY4Tpc44hSXO|YYm= MoHHNVDDqM7:TR?= MWixxsBp M2HjZmROW09? NFzkOZhqdmirYnn0d{ByfWmwYXPybY5mNWmwZIXj[YQheDN6IF3BVGsheGixc4Doc5J6dGG2aX;u NHrpfFMzPTZ6NEC0Ny=>
PANC-1 MWjGeY5kfGmxbjDBd5NigQ>? MXqxNEDPxE1? M4HUZlEhcA>? NVjJSJB5\W6qYX7j[ZMhfGinIHH1eI9xcGGpaXOg[YZn\WO2wrC= MUWyOVY{OjJ{Mh?=
BxPC-3 NXHsW4VMTnWwY4Tpc44hSXO|YYm= M3z0dFExKM7:TR?= MknENUBp M1rxXIVvcGGwY3XzJJRp\SCjdYTvdIhi\2mlIHXm[oVkfMLi MXKyOVY{OjJ{Mh?=
K562  NEjkO5RHfW6ldHnvckBCe3OjeR?= MlrvNE4zPS1zIN88US=> M2PBcFI1KGh? Ml:0d5VxeHKnc4Pld{Bz\XO4ZYLheJJwdC2rbnT1Z4VlKEh{QWigdIhwe3Cqb4L5cIF1cW:w NFvSdlMzPTZzOUO5Ni=>
THP-1 MXvGeY5kfGmxbjDBd5NigQ>? M4PvUFUhyrWP NG\qRoMzKGh? MmXQd4lodmmoaXPhcpRtgSCjdITlcpVifGW|IIPlZ5JmfGmxbjDv[kBKVC1zzsGgbY5lfWOnZDDifUAzP0:KQ3jvcEBxdHW|IF\TUE0yyqB? NIDBN5MzPTV7OE[2NS=>
WB NULnb5hOTnWwY4Tpc44hSXO|YYm= MWWyNQKBkc7:TdMg M13XR|Mx6oDLbXnu NIrCXlVl\WO{ZXHz[ZMhfGinIFzQV{0hd3JiTGTBMYlv\HWlZXSgTWwuPiCjbnSgWG5HNc7zwrDwdo9lfWO2aX;u MnX2NlU2OzB4OEK=
RAW 264.7 NHfDVG5HfW6ldHnvckBCe3OjeR?= M4PuRlExyqEQvF2= MVmzNQKBkW2rbh?= MlOzbY5lfWOnczDjbIFz[WO2ZYLpd5Rq[yC4YXP1c4xifGmxbjDv[kBQS3QEoB?= MViyOVQ3OTN7OR?=
RAW 264.7 M2ezVGZ2dmO2aX;uJGF{e2G7 NFW0T|MyOMLizszN M4HnWFMx6oDLbXnu M1LUboF1fGWwdXH0[ZMhfGinIHXm[oVkfHNib3[gU3BIKG:wIH;zeIVw[2yjc4SgdoV1emGldHnvci=> NETueZkzPTR4MUO5PS=>
HaCaT  NFKyNVNHfW6ldHnvckBCe3OjeR?= NEn1e4s1OMLizszN MXmzMVI1KGh? MXjEUXNQ M4GwXpJm\HWlZYOgeIhmKGGlY4XteYxifGmxbjDv[kBbVy1z MkLKNlU1OzV2OEW=
H9c2 M{LTTmZ2dmO2aX;uJGF{e2G7 NWHjfHc{PTEEoN88UeKh MUexNkBp NXK4VFdnemWmdXPld{BNTEhicnXs[YF{\SCjbnSgUW1RKGyxc4O= NGW0dmgzPTJ2NUixPC=>
HSCs NWnRR|hySXCxcITvd4l{KEG|c3H5 MmLYNlUh|ryP MYOyOOKhcA>? MmjZd4lodmmoaXPhcpRtgSCjdITlcpVifGW|IGTHMYlv\HWlZXSgZYN1cX[jdHXkJGhUS3NiYYDvdJRwe2m| MoHBNlQ6PjF7NUC=
THP-1 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWDqZmpRPzJiaB?= M4nUT2ROW09? M2jwcmlEPTB;ND63{txO NULD[HFNOjR6MUWwPFc>
MDDCs NWXvS5FKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn7WO|IhcA>? Ml3pSG1UVw>? NGrsTWFKSzVyMj63{txO MWKyOFgyPTB6Nx?=
MDDCs MkL0SpVv[3Srb36gRZN{[Xl? NF3T[5MxNTF3IN88US=> MnHIOFghcA>? MmLhSG1UVw>? NGPo[|F{fXCycnXzd4V{KEmITj5OtUBidmRiSWCtNVAheHKxZIXjeIlwdsLi M4\XdVI1QDF3MEi3
MDDCs NYrucXNlTnWwY4Tpc44hSXO|YYm= MYewMVE2KM7:TR?= M3fRS|Q5KGh? MmXaSG1UVw>? NUDkSpI2cW6qaXLpeJMhVUmSLUHhMEBOUVBvMXKgZY5lKFKDTmTFV{Bxem:mdXP0bY9v NUi1fHNROjR6MUWwPFc>
MDDCs MYLGeY5kfGmxbjDBd5NigQ>? NIjjdokyOCEQvF2= MUSzMlUhcA>? MkSzSG1UVw>? M2Hw[oJtd2OtczDFRm9XKEeSLDDieZQhdm:2IG\TWkBIKG2nZHnheIVlKGWwdIL5JIlvfG9iaIXtZY4hVUSGQ4O= MWeyOFgyPTB6Nx?=
macrophages MkPLSpVv[3Srb36gRZN{[Xl? MnO3NgKBkc7:TR?= M1HpelQvPeLCiXi= NVWy[3dM[2:vcHzleIVtgSCrbnjpZol1eyCPVD3JTWkucW6mdXPl[EBi[3SrdnH0bY9vKG:oIF7GMe67Sg>? NH[xUnAzPDhyOE[zNy=>
PDL  NV3jdFR[TnWwY4Tpc44hSXO|YYm= MWCyNOKh|ryPwrC= M1zNTlMxKG2rbh?= NFfm[JBFVVOR NVX1d3Fwe2mpbnnmbYNidnSueTDpcohq[mm2czD0bIUhfGWwc3ns[UBnd3KlZT3t[YRq[XSnZDDCUXAuOiCneIDy[ZN{cW:w Mk\jNlQ2PjFyOEG=
AGS NYjtRnhyTnWwY4Tpc44hSXO|YYm= MYC1JO69VQ>? NXzXfZpZOzBibXnu Mlrmd5VxeHKnc4Pld:KhOS2rbnT1Z4VlKGOjc4Dhd4UuQCCjbnSgZ4F{eGG|ZT2zJIFkfGm4YYTpc44> M3jtPVI1PTR5OEe4
H520 MVTGeY5kfGmxbjDBd5NigQ>? M2XIV|ExyqEEtV2= NGHBOY0yKGh? MVfEUXNQ MVjk[YNz\WG|ZYOgeIhmKHCnbXX0doV5\WRvaX7keYNm\CCPU1iyJI1TVkFiYX7kJJBzd3SnaX6gcIV3\Wy| MXOyOFU{ODR5NR?=
H1703 NIDVbHNHfW6ldHnvckBCe3OjeR?= M{PQUVExyqEEtV2= M1jMb|EhcA>? NWC4WXlZTE2VTx?= NI\PV5Rl\WO{ZXHz[ZMhfGinIIDlcYV1emW6ZXStbY5lfWOnZDDNV2gzKG2UTlGgZY5lKHC{b4TlbY4hdGW4ZXzz NXrVWlViOjR3M{C0O|U>
H520 NWew[nZoTnWwY4Tpc44hSXO|YYm= MkKwNVDDqML3TR?= MmXCNVIhcA>? NETIbphFVVOR NW\SRYJKcW6qaXLpeJMheGWvZYTy[Zhm\C2nbHnjbZRm\CCPU1iyJJBzd3SnaX6gd5Ri[mmuaYT5 MlTuNlQ2OzB2N{W=
H1703 NXLWOnFnTnWwY4Tpc44hSXO|YYm= NFHiZY4yOMLiwsXN NVGzU2FwOTJiaB?= MmnBSG1UVw>? NUnUTXNlcW6qaXLpeJMheGWvZYTy[Zhm\C2nbHnjbZRm\CCPU1iyJJBzd3SnaX6gd5Ri[mmuaYT5 NF:w[ZczPDV|MES3OS=>
H520 NY\sWmZRTnWwY4Tpc44hSXO|YYm= M4nIclExyqEEtV2= MXu2JIg> NGrvTmhFVVOR NYnXNIZve2mpbnnmbYNidnSueTDpcoNz\WG|ZYOgeIhmKGyndnXsd{Bw\iC3YnnxeYl1cW5vY3;ubpVo[XSnZDDNV2gzKGmwIIDlcYV1emW6ZXSteJJm[XSnZNMgZ4VtdCCuaX7l M{XxU|I1PTNyNEe1
H1703 NIXMWoRHfW6ldHnvckBCe3OjeR?= M2PabFExyqEEtV2= M{myNlYhcA>? MVXEUXNQ MlvQd4lodmmoaXPhcpRtgSCrbnPy[YF{\XNidHjlJIxmfmWuczDv[kB2[mmzdXn0bY4u[2:waoXnZZRm\CCPU1iyJIlvKHCnbXX0doV5\WRvdILlZZRm\MLiY3XscEBtcW6n MmDhNlQ2OzB2N{W=
MC3T3-E1 M13EN2Z2dmO2aX;uJGF{e2G7 NUPHbmdGOC5|L{OvN|Ah|ryP NX\YTnh7OSCq Mn3qZZR1\W63YYTld{BVVkZvzsGtbY5lfWOnZDDNUXAuQSCneIDy[ZN{cW:wIHnuJIEh[2:wY3XueJJifGmxbj3k[ZBmdmSnboSgcYFvdmW{wrC= M3HrfVI1PTB{Nkm2
MC3T3-E1 Ml3HSpVv[3Srb36gRZN{[Xl? MVyzNEDPxE1? M{nqZlEhcA>? MXnheJRmdnWjdHXzJHRPTi4QsT3zeIlufWyjdHXkJJA{QCCPQWDLJJBpd3OyaH;yfYxifGmxbh?= M1nVTFI1PTB{Nkm2
HUVECs  MYjGeY5kfGmxbjDBd5NigQ>? MlvmNVDDqML3TR?= MlrNNUBp MVzpcohq[mm2czDUUmYu|rFvaX7keYNm\CCFWFPMNUBxem:mdXP0bY9v NFfWdG8zPDR6N{m2OC=>
AGS  M2nxcWZ2dmO2aX;uJGF{e2G7 M2TJ[lExyqEEtV2= NW\OTYxsOzEEoH3pci=> NITlV49qdmirYnn0d{BKVC1zzsKtbY5lfWOnZDDhZ5RqfmG2aX;uJI9nKHB|OB?= MYiyOFQ4QTZ6MR?=
MKN-45 MVTGeY5kfGmxbjDBd5NigQ>? NEX2VWoyOMLiwsXN MX2zNOKhdWmw MXvpcohq[mm2czDJUE0y|rJvaX7keYNm\CCjY4TpeoF1cW:wIH;mJJA{QA>? MlHwNlQ1Pzl4OEG=
AGS  M2[zW2Z2dmO2aX;uJGF{e2G7 MXGxNOKhyrWP NI[xNpQ{OMLibXnu MXvheJRmdnWjdHXzJGlNNTIQsj3pcoR2[2WmIFfBJINmdGxibXnndoF1cW:wIHHu[EBqdn[jc3nvci=> NYC3Vpd5OjR2N{m2PFE>
MKN-45 NV;3fmJ5TnWwY4Tpc44hSXO|YYm= NFe1R5UyOMLiwsXN NHjTXnA{OMLibXnu MoHYZZR1\W63YYTld{BKVC1zzsKtbY5lfWOnZDDHRUBk\WyuIH3p[5JifGmxbjDhcoQhcW64YYPpc44> M{H3TlI1PDd7Nkix
AGS  NV31WHVyTnWwY4Tpc44hSXO|YYm= M4ny[lExyqEEtV2= MljvN|DDqG2rbh?= M3TmXJNq\26rZnnjZY51dHliZHXjdoVie2W|IFnsMVHPui2rbnT1Z4VlKE2PUEKgZY5lKE2PUEmgcXJPSSCneIDy[ZN{cW:w NWPGTZlLOjR2N{m2PFE>
MKN-45 NFrtbZBHfW6ldHnvckBCe3OjeR?= MXSxNOKhyrWP NVz4d2IxOzEEoH3pci=> MVLzbYdvcW[rY3HueIx6KGSnY4LlZZNmeyCLbD2x{tIucW6mdXPl[EBOVVB{IHHu[EBOVVB7IH3SUmEh\XiycnXzd4lwdg>? Moe4NlQ1Pzl4OEG=
DCs M{PRVWZ2dmO2aX;uJGF{e2G7 MkDENlDDqM7:TR?= NYTX[VJ{OcLiaB?= NV\QdoJq\GWlcnXhd4V{KEmOLUGyJJBzd2S3Y4Tpc44> M3fq[VI1PDN2NkO2
HUVEC  MYLGeY5kfGmxbjDBd5NigQ>? MWSyNEDPxG4EoB?= MWG1JIg> Mn;NSG1UVw>? Mn6wdoVlfWOnczDjfZRwc2mwZTDlfJBz\XO|aX;uJIxmfmWuczDpckBiKGOxbnPlcpRz[XSrb36t[IVx\W6mZX70JI1idm6nch?= MXKyOFE5QTB4Mh?=
A 549 MlLjSpVv[3Srb36gRZN{[Xl? NHT2RY82OCEQvF2= NF;xeZQyKGh? M3\WeoRm[3KnYYPld{B1cGVibHX2[Ywhd2ZiSVytPOKh MVqyOFE4QTZ6OB?=
H520  NX[yWoxpTnWwY4Tpc44hSXO|YYm= M3rmRVUwOTBizszN MnixNUBp NFvod4FFVVOR MmXD[IVkemWjc3XzJG1UUDJicILveIVqdiCjczD3[YxtKGG|IH3SUmEhdGW4ZXzzJIlvKGenZnn0bY5q[i2neIDvd4VlKGOnbHy= M4\FRVI1OTN6OUCz
H1703  NHrxd4VHfW6ldHnvckBCe3OjeR?= NUjBT2plPS9zMDFOwG0> MnrQNUBp M1K0fWROW09? M2TW[oRm[3KnYYPld{BOW0h{IIDyc5RmcW5iYYOge4VtdCCjczDtVm5CKGyndnXsd{BqdiCpZX\peIlvcWJvZYjwc5Nm\CClZXzs NGW4UmgzPDF|OEmwNy=>
H520  MkLxSpVv[3Srb36gRZN{[Xl? M1PNWFExyqEEtV2= NELhO4EyOiCq MorhSG1UVw>? NEPoZ21l\WO{ZXHz[ZMhVVOKMjDtVm5CKGGwZDDwdo91\WmwIIP0ZYJqdGm2eTDpckBo\W[rdHnubYIufHKnYYTl[EBPW0OOQzDj[Yxtew>? MY[yOFE{QDlyMx?=
H1703  NWroUoNzTnWwY4Tpc44hSXO|YYm= M1[yPFExyqEEtV2= NGjQRmwyOiCq MorSSG1UVw>? NVnEWZls\GWlcnXhd4V{KE2VSEKgcXJPSSCjbnSgdJJwfGWrbjDzeIFjcWyrdImgbY4h\2WoaYTpcoljNXS{ZXH0[YQhVlOFTFOgZ4VtdHN? M1HhR|I1OTN6OUCz
MCF-7  NXK4ZpRWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWqxNOKh|ryP NFL2eJMzPMLiaB?= MX\pcohq[mm2czD0bIUhS1JzMEitbY5lfWOnZDDj[YxtKGSnYYTo MorXNlQyOjh6NUO=
HPAEpiCs MUHGeY5kfGmxbjDBd5NigQ>? MVqwMlEwOS9zMDFOwG0> NYe2U3NTOSCq Mn;BbY5pcWKrdIOgWG5HNc7zLXnu[JVk\WRiY2DMRVLDqHC{b4TlbY4h[W6mIH3SUmEh\XiycnXzd4lwdg>? NYTQbXEyOjRyNkmxOVg>
podocytes NI\MVZdHfW6ldHnvckBCe3OjeR?= NWm4SZFlOTEEoN88US=> NYD6[4FiOSCq M2\NdIlvcGmkaYTzJHRITs7{MT3pcoR2[2WmIHHjeIl3[XSrb36gc4YheDN6TVHQT{BidmRiRYLrNU8zyqB? MX:yOFA{PjJzMh?=
MCF-7 NGr0VXVHfW6ldHnvckBCe3OjeR?= MY[xNOKh|ryP NEezboEyKGh? MorhSG1UVw>? MVry[YR2[2W|IITo[UBYSS2rbnT1Z4VlKHCqb4PwbI9zgWyjdHXkJJA{QCCPQWDL NXi0VJV[OjRyMUmwPVA>
MCF-7 NXPMSlUyTnWwY4Tpc44hSXO|YYm= NVTLVYdZOTEEoN88US=> MYWyOEBp NH\Jc2ZFVVOR NGDqTmJqdmO{ZXHz[ZMhfGinIGfBMYlv\HWlZXSgZZBweHSxc3nz NVvQTHE2OjRyMUmwPVA>
HAPI NGK1dGVHfW6ldHnvckBCe3OjeR?= MnfqNVAwOjBxNEFCpO69VQ>? M4HpelEhcA>? MWDpcohq[mm2czDUR2RFNWmwZIXj[YQheDN6L1rOT{BOSVCNIIDoc5NxcG:{eXzheIlwdg>? MlfINlM6PjlzMkC=
HAPI MmDJSpVv[3Srb36gRZN{[Xl? NX\DepdlOjEEoN88UeKh MnzoNUBp M2LKemROW09? MmHPZZR1\W63YYTld{BVS0SGLXnu[JVk\WRiYXP0bZZifGmxbjDv[kBqVk:VIHHu[EBxem:mdXP0bY9v NU\EXlZ7OjN7NkmxNlA>
HepG2 NIHoVmxHfW6ldHnvckBCe3OjeR?= M1S2PVM2OCCwTR?= MUGyOEBp M1rNS4lvcGmkaYTzJJRp\SCmZXf1[Yxqdi2rbnT1Z4VlKGGldHn2ZZRqd25ib3[gdFM5VUGSSx?= M4O4PFI{QTN|MUm4
AGS  MkjRSpVv[3Srb36gRZN{[Xl? M1;HeVExyqEQvF2= M1v4WFMxKG2rbh?= MnnFbY5pcWKrdIOgZ4F{eGG|ZT2zJIFkfGm4YYTpc44h[W6mIHnubIljcXSrb36gc4YhTVKN M4f0cFI{QDVyOUm0
HepG2 MnfsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2jCXFAuPTBizszN NYPUSI9[PDhiaB?= M3zXR4lvcGmkaYTzJJRp\SCycn;sbYZmemG2aX;uJIlvKGFiZH;z[UBl\XCnbnTlcpQhdWGwbnXy MXuyN|gxPzVyOB?=
BEL7404 M33wPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3ToPVAuPTBizszN MnnJOFghcA>? NF\xW5ZqdmirYnn0d{B1cGVicILvcIln\XKjdHnvckBqdiCjIHTvd4Uh\GWyZX7k[Y51KG2jbn7ldi=> Mn[4NlM5ODd3MEi=
HL7702 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoHQNE02OCEQvF2= MWO0PEBp M2PETolvcGmkaYTzJJRp\SCycn;sbYZmemG2aX;uJIlvKGFiZH;z[UBl\XCnbnTlcpQhdWGwbnXy NYf6V5VNOjN6MEe1NFg>
HepG2 MW\GeY5kfGmxbjDBd5NigQ>? M2Gw[VAuPTBizszN NGO1SYQzPCCq M{jZWolvcGmkaYTzJJRp\SCyaH;zdIhwenmuYYTpc44hd2ZicEO4JIRwf26|dILlZY0heHKxdHXpcpMhVUGSS1HQT|ItKEGWRkKsJG1UUzFiYX7kJGhUWDJ5IHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ NWDwZlhHOjN6MEe1NFg>
BEAS-2B MlraS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M37nNVExKM7:TR?= MWKzNEBucW5? NVLmSXFXemW4ZYLz[ZMhfGinIHTlZ5Jm[XOnIH;mJINmdGxidnnhZoltcXS7IHnu[JVk\WRiYomgTGNK Mk\zNlM4QDRyM{S=
BEAS-2B Mn7lR5l1d3SxeHn0fUBCe3OjeR?= MoXTNVAh|ryP Ml3iN|AhdWmw M4fZfolvcGmkaYTl[EB1cGViaX7jdoVie2ViaX6gUGRJKGGwZDDJUE05KGW6cILld5Nqd25? M1rtVVI{Pzh2MEO0
BEAS-2B Mn;aSpVv[3Srb36gRZN{[Xl? NUjqOod[OTBizszN NYG4Oo5tOzBibXnu M3TFO4Rm[3KnYYPld{B1cGVibHX2[Yx{KG:oIHPhd5Bie2VvMzygRoFlKGGwZDDmZZM> NWn1S5UxOjN5OESwN|Q>
H9c2  NVfQSJZ{TnWwY4Tpc44hSXO|YYm= MXSwMlAyNzBwMT:xJO69VQ>? MVqxJIg> MlrYZZR1\W63YYTld{BVVkZvzsGtbY5lfWOnZDDNUXAuQSCneIDy[ZN{cW:wLDDtVm5CKGyndnXsd{wh[W6mIIDyc41wfGW{IHHjeIl3cXS7 M{P0TVI{Pzd2MkWy
H9c2  Mn;wSpVv[3Srb36gRZN{[Xl? MX2xJO69VQ>? MlzqNUBp NX;SV3dsemWmdXPld{BVVkZvzsGg[Ilz\WO2bImgd5RqdXWuYYTl[EBxOzhiTVHQT{BxcG:|cHjvdplt[XSrb36= MWWyN|c4PDJ3Mh?=
U937 Ml;uSpVv[3Srb36gRZN{[Xl? M33SR|ExyqEQvF5CpC=> M{XwVVEhcA>? M{C2TYFjem:pYYTld{B1cGViY3Hm[oVqdmViZX\m[YN1KG:wIF3LVE0yKGGwZDDQVFJC[87zIH3SUmEhfHKjboPjdolxfGmxbnHsJIxmfmWucx?= NWTvW5UxOjN5MEezPFc>
U937 NHLoZ3hHfW6ldHnvckBCe3OjeR?= NYS1ZnpROTEEoN88UeKh MWexJIg> M2TafIFjem:pYYTld{Bk[W[oZXnu[U1qdmS3Y3XkJG1MWC1zIHTve44uemWpdXzheIlwdiCjbnSgVHAzSWQQsTD1dE1z\We3bHH0bY9v MmPINlM4ODd|OEe=
U937 NF\3fIRHfW6ldHnvckBCe3OjeR?= MWGxNOKh|ryPwrC= MXyxJIg> MmC5d5VxeHKnc4Pld{BkNUq3bjDhcoQhS1KHQjDwbI9{eGixconsZZRqd25iaX6gZ4Fn\mWrbnWteJJm[XSnZDDj[Yxte8Li MnTBNlM4ODd|OEe=
A549 M1nRZ2Z2dmO2aX;uJGF{e2G7 NHPVWlgxNjNxMz:zNEDPxE1? Ml;ZNUBp M1XLOpNq\26rZnnjZY51dHliYYT0[Y52[XSnczDBWHDPu1NvbXXkbYF1\WRiQ1;YMVIheHKxdHXpckBidmRibWLORUBmgHC{ZYPzbY9vKGGwZDDwdo9ud3SncjDhZ5Rqfmm2edMg MYSyN|Y5ODZ5NB?=
A549 NInv[WVHfW6ldHnvckBCe3OjeR?= NV;xXFZWOTEEoN88UeKh Mme0NE0{OCCvaX6= M2\JdYlvcGmkaYTzJGFVWM7|UzDpcoR2[2WmIIC0Nk9xPDRiTVHQT{BidmRicEO4JG1CWEticHjvd5Bpd3K7bHH0bY9v MYCyN|Y5ODZ5NB?=
A549 NV;r[Jd2TnWwY4Tpc44hSXO|YYm= MnrkNVDDqM7:TdMg NFLXd4oyKGh? NWj2fI1zcW6qaXLpeJMhSVSSzsPTJIlv\HWlZXSgUmYu|rqEIIC2OUB{fWK3bnn0JJBpd3OyaH;yfYxifGmxbjDhcoQhVkZvzsrCJJBzd22xdHXyJIFkfGm4aYT5 MUmyN|Y5ODZ5NB?=
A549 MlTzSpVv[3Srb36gRZN{[Xl? MUexNOKh|ryPwrC= NUXwOpB2OSCq NUHQZ4lyemWmdXPld{BCXFEQs2Otd5RqdXWuYYTl[EBkWEyDMjDwbI9{eGixconsZZRqd28EoB?= NH6wWGMzOzZ6ME[3OC=>
A549 NE\hZZpHfW6ldHnvckBCe3OjeR?= Ml[0NVDDqM7:TdMg NFXBfFQyKGh? NWrjfXJFemWmdXPld{BCXFEQs2Ot[Y5p[W6lZXSg[Y57gW2jdHnjJIFkfGm4aYT5JI9nKGOSTFGyxsA> MXGyN|Y5ODZ5NB?=
PC12 NVrLRWh5TnWwY4Tpc44hSXO|YYm= NYXqdFJnOTBxMkCvOFAh|ryP MWixxsBp MUDpcohq[mm2czDKUmsh[W6mIICzPC=> MkXxNlM2QDR|NUe=
HK-2 MWfBdI9xfG:|aYOgRZN{[Xl? Mn34NlDDqM7:TR?= M2rwSlI1KGh? M1LKeYlvcGmkaYTzJGVTUyCjbnSgdFM5VUGSSx?= Mo\KNlM2PDNzNUG=
H9c2 NH[5T5ZHfW6ldHnvckBCe3OjeR?= MWOxxsDPxE1? M3u4VlEhcA>? Mm\HdoVlfWOnczDUUmYu|rFvaX7keYNm\CCPTWCtPUBuWk6DIHzleoVteyCjbnSgdJJwdW:2ZYKgZYN1cX[rdIm= MXmyN|M2OzZ7OR?=
H9c2 M3r5PGZ2dmO2aX;uJGF{e2G7 NX7VN49QOcLizszN MnKyNUBp MlP2doVlfWOnczDUUmYu|rFvZX7oZY5k\WRiQWCtNUBxem:vb4TldkBi[3Srdnn0fS=> NFHONVEzOzN3M{[5PS=>
H1650  MVvGeY5kfGmxbjDBd5NigQ>? MX[xNOKh|ryPwrC= NYC1N4FiOSCq NVfFcmd5TE2VTx?= MYTk[YNz\WG|ZYOgZo91cCCycn;0[YlvKGGwZDDtVm5CKGyndnXsd{Bw\iCHUlPDNUBqdiCyYXPsbZRigGWuLXX4dI9{\WUEoHPlcIx{ NUPkd|d6OjN{Mki2PVY>
H1703 MYTGeY5kfGmxbjDBd5NigQ>? NH;oUFAyOMLizszNxsA> NYHzVVBHOSCq MmWwSG1UVw>? M1vrTYRm[3KnYYPld{Bjd3SqIIDyc5RmcW5iYX7kJI1TVkFibHX2[Yx{KG:oIFXSR2MyKGmwIIDhZ4xqfGG6ZXyt[Zhxd3OnZNMgZ4VtdHN? M3nyNVI{OjJ6Nkm2
H1650  NGrJeoJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkXGNVDDqM7:TdMg MnrENUBp MV\EUXNQ NX7KVYZW\W6qYX7j[ZMheGGlbHn0ZZhmdC2rbnT1Z4VlKGO7dH;0c5hq[2m2eR?= MnfTNlMzOjh4OU[=
H1703 NFS0b29Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1K4eFExyqEQvF5CpC=> MVqxJIg> NG\iTWVFVVOR MYDlcohidmOnczDwZYNtcXSjeHXsMYlv\HWlZXSgZ5l1d3SxeHnjbZR6 MWeyN|IzQDZ7Nh?=

... Click to View More Cell Line Experimental Data

In vivo Inhibiting p38 by administration of SB 202190 inhibits PV IgG-induced blister formation in the passive transfer mouse model. [5] In the endotoxin model of sepsis, SB 202190 treatment produces a statistically significant survival benefit compared with control. [8]

Protocol

Kinase Assay:

[1]

+ Expand

In vitro kinase assays:

The p38α and p38β are assayed in 25 mM Tris-HCl, pH 7.5, containing 0.1 mM EGTA, with myelin basic protein (0.33 mg/mL) as substrate. Assays are performed either manually for 10 minutes at 30 °C in 50 μL incubations using [γ-33P]ATP, or with a Biomek 2000 Laboratory Automation Workstation in a 96-well format for 40 minutes at ambient temperature in 25 μL incubations using [γ-33P]ATP. The concentrations of ATP and magnesium acetate are 0.1 mM and 10 mM respectively. All assays are initiated with MgATP. Manual assays are terminated by spotting aliquots of incubation on to phosphocellulose paper, followed by immersion in 50 mM phosphoric acid. Robotic assays are terminated by the addition of 5 μL of 0.5 M phosphoric acid before spotting aliquots on to P30 filter mats. All papers are then washed four times in 50 mM phosphoric acid to remove ATP, once in acetone (manual incubations) or methanol (robotic incubations), and then dried and counted for radioactivity.
Cell Research:

[2]

+ Expand
  • Cell lines: Jurkat, and HeLa
  • Concentrations: Dissolved in DMSO, final concentrations ~50 μM
  • Incubation Time: 24 hours
  • Method:

    Cells are serum-starved and then treated with different concentration of SB 202190 for 24 hours. Cell viability is assayed by either trypan blue exclusion or propidium iodide exclusion followed by flow cytometry analysis. The apoptotic nuclei are visualized by H33258 staining.


    (Only for Reference)
Animal Research:

[5]

+ Expand
  • Animal Models: C57BL/6J mice injected i.d. with a sterile solution of either control IgG or PV IgG
  • Formulation: Dissolved in DMSO, and diluted in saline
  • Dosages: 12.5 μg
  • Administration: Administered via i.d.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 66 mg/mL (199.19 mM)
Ethanol 12 mg/mL (36.21 mM)
Water Insoluble
In vivo Add solvents to the product individually and in order:
1% DMSO+30% polyethylene glycol+1% Tween 80
For best results, use promptly after mixing.
30 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 331.34
Formula

C20H14N3OF

CAS No. 152121-30-7
Storage powder
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

p38 MAPK Signaling Pathway Map

p38 MAPK Inhibitors with Unique Features

Related p38 MAPK Products

Tags: buy SB202190 (FHPI) | SB202190 (FHPI) supplier | purchase SB202190 (FHPI) | SB202190 (FHPI) cost | SB202190 (FHPI) manufacturer | order SB202190 (FHPI) | SB202190 (FHPI) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID